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Spinocerebellar ataxia type 3 is a neurodegenerative disorder caused by the expansion of the polyglutamine repeat region within
the ataxin-3 protein. The mutant protein forms intracellular aggregates in the brain. However, the cellular mechanisms causing
toxicity are still poorly understood and there are currently no effective treatments. In this study we show that administration of
a rapamycin ester (cell cycle inhibitor-779, temsirolimus) improves motor performance in a transgenic mouse model of spino-
cerebellar ataxia type 3. Temsirolimus inhibits mammalian target of rapamycin and hence upregulates protein degradation by
autophagy. Temsirolimus reduces the number of aggregates seen in the brains of transgenic mice and decreases levels of
cytosolic soluble mutant ataxin-3, while endogenous wild-type protein levels remain unaffected. Temsirolimus is designed
for long-term use in patients and therefore represents a possible therapeutic strategy for the treatment of spinocerebellar
ataxia type 3. Using this disease model and treatment paradigm, we employed a microarray approach to investigate transcrip-
tional changes that might be important in the pathogenesis of spinocerebellar ataxia type 3. This identiﬁed ubiquitin speciﬁc
peptidase-15, which showed expression changes at both the messenger ribonucleic acid and protein level. Ubiquitin speciﬁc
peptidase-15 levels were also changed in mice expressing another mutant polyglutamine protein, huntingtin. In total we
identiﬁed 16 transcripts that were decreased in transgenic ataxin-3 mice that were normalized following temsirolimus treatment.
In this mouse model with relatively mild disease progression, the number of transcripts changed was low and the magnitude of
these changes was small. However, the importance of these transcriptional alterations in the pathogenesis of spinocerebellar
ataxia type 3 remains unclear.
Keywords: Usp15; microarray; rapamycin; huntingtin; polyglutamine
Abbreviations: Alcam=activated leukocyte cell adhesion molecule; Alkbh5=alkylation repair homolog 5; Bcas3=Breast carcinoma
ampliﬁed sequence 3; Bcl2l11=B cell lymphoma protein 2 like 11; Dgki=Diacylglycerol kinase, iota; EGFP=enhanced green
ﬂuorescent protein; Grik2=Glutamate receptor, ionotropic, kainate 2 (beta 2); LC=light chain; Mef2c=Myocyte enhancer factor
2C; Mnab1=membrane associated DNA binding protein; mTOR=mammalian target of rapamycin; Myh9=myosin, heavy
polypeptide 9, non-muscle; RORa=retinoic acid receptor-related orphan receptor alpha; Sfpq=splicing factor proline/glutamine
rich; Usp=ubiquitin speciﬁc peptidase
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Spinocerebellar ataxia type 3 (Machado–Joseph disease), is among
the commonest of the autosomal dominant spinocerebellar ataxias
worldwide (Schols et al., 2004). It is a devastating neurodegen-
erative disorder resulting from the expansion of the polyglutamine
repeat region of the ataxin-3 gene. It shares many features
with the eight other diseases caused by polyglutamine expansion
mutations, including Huntington’s disease, such as the formation
of inclusions within neurons by the mutant protein. The exact
mechanism by which mutant ataxin-3 causes cellular toxicity is
unknown. One potential pathogenic mechanism involved in
polyglutamine repeat disorders is transcriptional dysregulation
(reviewed in Sugars and Rubinsztein, 2003; Riley and Orr, 2006).
Polyglutamineaggregates, including ataxin-3aggregates, havebeen
demonstrated to sequester transcription factors (Perez et al., 1998).
Ataxin-3 may also have a more direct role in transcription regulation
through its interactions with histone acetyltransferases (Li et al.,
2002) and histone deacetylases (Evert et al., 2006).
The normal role of ataxin-3 appears to be within the ubiquitin
signalling system. The protein has two ubiquitin interacting motifs
(or three in the shorter splice variant) (Albrecht et al., 2004) and
additionally there are two ubiquitin binding sites in the Josephin
domain (Nicastro et al., 2009). Ataxin-3 has been demonstrated to
possess ubiquitin protease activity (Burnett et al., 2003) and it may
be involved in delivery of ubiquitinated substrates to the protea-
some for degradation (Doss-Pepe et al., 2003). In particular,
ataxin-3 may be important in the regulation of endoplasmic reti-
culum associated protein degradation, removing mis-folded
proteins from the endoplasmic reticulum (Wang et al., 2006;
Zhong and Pittman, 2006). Overexpression of wild-type ataxin-3
suppresses toxicity in Drosophila models of polyglutamine
mediated neurodegeneration (Warrick et al., 2005) and this was
hypothesized to result from an increased turnover of the mutant
polyglutamine proteins.
The ubiquitin protease activity of ataxin-3 is not altered by the
presence of the expanded polyglutamine repeat in the mutant
protein (Burnett et al., 2003; Chai et al., 2004; Todi et al.,
2009). In fact, polyglutamine mutations appear to cause disease
predominantly by toxic gain-of-function effects (Imarisio et al.,
2008). Furthermore, two copies of the mutant ataxin-3 gene
have been reported to result in more severe disease in spinocer-
ebellar ataxia type 3 (Carvalho et al., 2008). Thus, we have con-
sidered that reducing the levels of toxic proteins by enhancing the
degradation of the mutant allele relative to the wild-type allele
may be a possible therapeutic strategy for this group of diseases.
This may be possible by inducing macroautophagy (which we
will call autophagy). Along with degradation by the proteasome,
autophagy forms the major route for degradation of cellular pro-
teins. Autophagy begins with the formation of double-membraned
structures called autophagosomes in the cytosol, which ultimately
fuse with lysosomes to degrade their contents. Previously, we and
others have shown in tissue culture and in Drosophila that a range
of aggregate-prone, polyglutamine-expanded constructs (including
mutant huntingtin fragments, full-length mutant huntingtin and
full-length mutant ataxin-3) are highly dependent on autophagy
for their clearance (Ravikumar et al., 2002; Berger et al., 2006;
Shibata et al., 2006). When autophagy is blocked either chemi-
cally or genetically, these proteins accumulate. Interestingly, the
clearance of wild-type forms of mutant huntingtin has little or
no dependence on autophagy (Ravikumar et al., 2002; Shibata
et al., 2006).
Autophagy can be up-regulated by inhibiting the mammalian
target of rapamycin (mTOR) or by mTOR-independent pathways
(Noda and Ohsumi, 1998; Sarkar et al., 2005; Boland et al., 2008;
Williams et al., 2008). Both rapamycin (a speciﬁc mTOR inhibitor)
and drugs acting on mTOR-independent pathways enhance the
clearance of mutant polyglutamine proteins (including full-length
mutant ataxin-3) in cell culture (Sarkar et al., 2005; Berger et al.,
2006; Williams et al., 2008). We have shown in cells, Drosophila
and zebraﬁsh, that autophagy up-regulation decreases soluble
levels of aggregate-prone proteins, decreases the proportion of
cells with inclusions and attenuates toxicity (Ravikumar et al.,
2004; Sarkar et al., 2005; Williams et al., 2008). We have also
shown that the rapamycin analogue temsirolimus (cell cycle
inhibitor-779) reduces aggregate number and behavioural
abnormalities in a transgenic mouse expressing a mutant hunting-
tin fragment when administered  6 weeks before the onset of
signs (Ravikumar et al., 2004). Temsirolimus is a rapamycin ester
designed for injection and shows the same activity as rapamycin
(sirolimus, Rapamune) (reviewed in Huang and Houghton,
2001). This ﬁnding raised the possibility that up-regulation of
autophagy may be an effective therapeutic strategy for a variety
of diseases caused by aggregate-prone intracytosolic proteins.
Here we have tested the efﬁcacy of temsirolimus in an expanded
full-length spinocerebellar ataxia type 3 mouse model adminis-
tered soon after the onset of disease signs.
Materials and methods
Mice and behavioural tests
All procedures were carried out under the jurisdiction of appropriate
UK Home Ofﬁce Project and Personal animal licences and with local
ethical committee approval. The generation of the mouse model
(spinocerebellar ataxia type 3 line 70.61) used here has been pre-
viously described (Bichelmeier et al., 2007). These mice overexpress
full-length human ataxin-3 with an expanded polyglutamine repeat
region of 70 amino acids under the control of the prion protein
promoter on a C57/BL6 background. Mice were genotyped at
3 weeks of age by PCR using published primers (Bichelmeier et al.,
2007). Male mice were selected for use in behavioural studies as they
demonstrated less variable performance in rotarod trials and hence a
more consistent phenotype than females (data not shown). Transgenic
and non-transgenic or drug and placebo treated animals were
matched within litters and housed in the same cage. Temsirolimus
(kind gift from Wyeth) was administered by intraperitoneal injections
three times a week at a dose of 20mg/kg (Ravikumar et al., 2004).
Control mice were given a placebo of injection buffer only with the
same frequency. Rotarod testing was carried out exactly as previously
described (Vacher et al., 2005). Placebo and drug treated mice within
each litter were tested on the rotarod simultaneously and at the time
of testing were not identiﬁed as to their treatment status.
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mouse line, HD-N171-N82Q [B6C3F1/J-Tg(HD82Gln)81Dbo/J,
Jackson Laboratory, Bar Harbour, ME] has been previously described
(Schilling et al., 1999; Vacher et al., 2005). These mice express exon 1
of Huntingtin with an expanded polyglutamine region of 82 amino
acids under the control of the prion protein promoter.
Culturing and treatment of primary
cortical neurons
For direct assessment of autophagy following rapamycin treatment
primary cortical neurons were isolated from embryonic day 16.5
Sprague Dawley rat pups (Charles River). Brieﬂy, pup brains were
harvested and placed in ice-cold Dulbecco’s modiﬁed eagle medium
where the meninges were removed; the cerebral cortices were
dissected and then incubated in Dulbecco’s modiﬁed eagle medium
containing Accutase (Innovative Cell Technologies, San Diego, CA)
for 10min at 37 C. After mechanical dissociation using sterile micro-
pipette tips, dissociated neurons were resuspended in Dulbecco’s
modiﬁed eagle medium and centrifuged. Cell count and viability
assay was performed using trypan blue. Viable cells were seeded on
a poly-D-lysine and laminin coated 6 multiwell (7.5 10
5 cells per
well). Cells were maintained in Dulbecco’s modiﬁed eagle medium
containing 2mM glutamine, 2% B27 supplement and 1% penicillin/
streptomycin/fungizone (Invitrogen). One-half of the plating medium
was changed every third day until treatment. After 7 days in vitro,
cultured neurons were treated for 8h with 0.2mM rapamycin (Sigma-
Aldrich). Where used, a saturating concentration (400nM) of
baﬁlomycinA1 (Calbiochem) was added to the cells in the last 4h
before harvesting.
Immunohistochemistry
For aggregate analysis, brains of 3 month old mice were perfusion
ﬁxed with 4% paraformaldehyde. Brains were then frozen and
12mm sections cut. Sections were post-ﬁxed for 10min with 4%
paraformaldehyde, blocked for 1h in block buffer (5% normal goat
serum, 1% bovine serum albumin 0.1% triton X-100 in phosphate
buffered saline) and incubated with primary antibody, mouse anti-
ataxin-3 (MAB5360, Millipore, Watford, Hertfordshire) diluted 1 in
1000 in block buffer overnight at 4 C. Primary antibody binding was
visualized by peroxidase labelling using vectastain elite avidin and
biotinylated enzyme complex kit with 3,30-diaminobenzidine substrate
following the manufacturers protocol (both from Vector Laboratories,
Burlingame, CA). Aggregates were counted in the motor cortex, as this
region showed clear accumulation of aggregates at a level that could
be accurately counted. Three ﬁelds (diameter of 1mm) were counted
on different sections of brains from ﬁve animals in each treatment
group (n=5). Statistical analysis was carried out by unpaired t-test.
For S6 staining, tissue was treated as above; primary antibody
was either anti-phospho-S6 or anti-total-S6 (both Cell Signaling
Technologies, Danvers, MA). Sections were then incubated in second-
ary antibody, goat-anti rabbit conjugated to alexa 488 (Invitrogen) for
1h at room temperature and then mounted in citiﬂuor (Citiﬂuor,
London) with 40,6-diamidino-2-phenylindole.
Protein extraction and western blotting
For autophagy analysis, cell pellets were lysed on ice in Laemmli
buffer (6.5mM Tris–HCl pH 6.8, 2% sodium dodecyl sulphate, 5%
b-mercaptoethanol, 10% glycerol and 0.01% bromophenol blue)
for 30min in presence of protease inhibitors (Roche Diagnostics).
Nuclear and cytoplasmic extracts were prepared from fresh brain
tissue using a nuclear extract kit (Active motif, Carlsbad, CA), follow-
ing the manufacturer’s protocol. Total brain lysates were prepared by
homogenising in buffer B (50mM Tris pH 7.5, 10% glycerol, 5mM
magnesium acetate, 0.2mM ethylenediaminetetraacetic acid, 0.5mM
dithiothreitol and protease inhibitor) at 4 C. The homogenate was
centrifuged at 13000g at 4 C, the supernatant was removed and
used for western blot analysis.
Samples were separated by sodium dodecyl sulfate polyacrylamide
gel electrophoresis, using a standard protocol and transferred to poly-
vinylidene ﬂuoride membrane (Millipore, Watford, Hertfordshire).
Membranes were incubated overnight with primary antibody followed
by peroxidase conjugated secondary antibody and detection using
Amersham electro or enhanced chemiluminescence substrate kit (GE
Healthcare, Little Chalfont, Buckinghamshire). Membranes were then
stripped using Re-Blot plus (Millipore) and reprobed with loading con-
trol antibody, either anti -tubulin clone DM1A or rabbit actin (both
Sigma, Poole, Dorset) or anti-histone H3 (Cell Signaling Technology,
Danvers, MA). Densitometric analysis was carried out using Image J
software. Primary antibodies used were mouse anti-ataxin-3 (Millipore,
Watford, Hertfordshire), rabbit anti-light-chain-3 (LC3: Novus
Biologicals), rabbit anti-phospho and total p70S6Kinase, rabbit anti-
phospho and total S6 ribosomal protein, rabbit anti-phospho and
total eukaryotic initiation factor 4E-binding-protein 1 (Cell Signaling
Technology), goat anti-ubiquitin speciﬁc peptidase (Usp)-15, rabbit
anti-Grik2, mouse anti-splicing factor proline/glutamine-rich and
rabbit anti-RORa (all Abcam, Cambridge) (see Table 1 for expansions).
Microarray methods
Mice were adminsistered temsirolimus or placebo as for behavioural
studies, from 5 weeks of age for a period of 6 weeks. Mice were then
sacriﬁced and brains dissected and snap frozen on dry ice. Microarray
experiments were performed on an Affymetrix platform. Fragmented
and labelled cRNA of the different groups (four wild-type—placebo
mice, ﬁve wild-type—temsirolimus mice; ataxin-3-placebo and
ataxin-3-temsirolimus) were hybridized on Affymetrix mouse
genome 430 2.0 arrays. A probe level summary was determined
using the Affymetrix GeneChip Operating Software using the
Microarray Analysis Software 5 algorithm. Normalization of raw data
was performed by the Array AssistSoftware 4.0 (Stratagene, La Jolla,
Canada), applying a robust multichip average algorithm with correc-
tion for guanine and cytosine content. Signiﬁcance was calculated
using a t-test without multiple testing correction (Array Assist
Software), selecting all transcripts with a minimum change in expres-
sion level of 1.5-fold together with a P-value50.05. When identifying
transcriptional changes between multiple treatment groups, genes
were selected based on changes in the same probe set and changes
in different probe sets corresponding to the same gene were not
included.
Real-time PCR
Initial validation was carried out on RNA samples isolated for micro-
array analysis. Quantitative real-time PCR was performed with the
QuantiTect SYBR green PCR kit (Qiagen, Hilden, Germany) in the
LightCycler 2.0 (Roche). Standard curves of each ampliﬁed gene
were created to calculate the PCR efﬁciency. Pyruvate dehydrogenase
(PDH), tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, zeta polypeptide (YWHAZ) and succinate dehydro-
genase complex, subunit A (SDHA) were analysed as the reference
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of the reference genes and the target genes were obtained with the
LightCycler Software 4.0 using the ‘Fit Points’ method. The relative
expression levels of all genes were calculated using the mathematical
model of Pfafﬂ (2001). Primers used were as follows: Grik2
(Glutamate receptor, ionotropic, kainate 2 (beta 2)) forward 50
AGTGCCACCATACCATCCAG 30, reverse 50 GCTGGC
ACTTCAGAGACATTC 30, PDH forward 50 GTAGAGGACACGGGCA
AGAT 30, reverse 50 TGAAAACGCCTCTTCAGCA 30, SDHA forward
50 GCAGCACAGGGAGGTATCA 30, reverse 50 CTCAACCACAGAGG
CAGGA 30, Tloc (translocation protein 1) forward 50 CATCGGGTTGA
CTATTTTATTGC 30, reverse 50 CCACAGACTCCCTGGTTGTAA 30,
Usp15 forward, 50 GAAGCTGGGTGCTGAGGA 30, reverse 50 CCAC
AGACTCCCTGGTTGTAA 30, YWHAZ forward 50 AGACGGAAG
GTGCTGAGAAA 30, reverse 50 TCAAGAACTTTTCCAAAAGAGACA 30.
For further analysis RNA from 3.5–4 month old mouse brains was
extracted using Trizol (Invitrogen). One micro gram RNA was used for
reverse transcription, performed with Supercript III kit (Invitrogen)
according to the manufacturer’s instructions. The quantitative PCR
reaction for green ﬂuorescent protein was carried out with SYBR
PCR mix (Applied Biosystems) and the following primer pairs, RORa
(Retinoic acid receptor-related orphan receptor alpha) forward
50 GAACACCTTGCCCAGAACAT 30, reverse 50 AGCTGCCACATCAC
CTCTCT 30, Sfpq (splicing factor proline/glutamine rich) 50 ACGATG
GAAGTCCTTGGATG 30, reverse 50 TCCATGCGCCTTAATTCTTC 30,
Mnab1 (membrane associated DNA binding protein) forward
50 CGAATGACCCAAGGACAACT 30, reverse 50 AGGAGAAGGTGGTG
TTGGTG 30, Mef2c (Myocyte enhancer factor 2C) forward 50 CCATTG
GACTCACCAGACCT 30, reverse 50 AGCACACACACACACTGCAA 30,
Dgki (Diacylglycerol kinase, iota) forward 50 ATGACATCCATC
AGGTGCAA 30, reverse 50 CCGGAGTTTGTCCTTGTCAT 30, Alcam2
(Breast carcinoma ampliﬁed sequence 3) forward 50 CTCGTTGCTG
GTGTCGTCTA 30, reverse 50 ATCCGCTCCTCTCTTAGGC 30, Bcas3
(Breast carcinoma ampliﬁed sequence 3) forward 50 GGAGAGCGT
CGTGACTTTTC 30, reverse 50 CAGAGGAGGCTCATTTCCAG 30,
Alkbh5 (alkylation repair homolog 5) forward 50 GGAACCTGTGCTT
TCTCTGC 30, reverse 50 TGCTCAGGGATTTTGTTTCC 30, Bcl2l11
(B cell lymphoma protein 2 (Bcl-2) like 11) forward 50 GCCCCTA
CCTCCCTACAGAC 30, reverse 50 TGGGGATCTGGTAGCAAAAG 30,
Myh9 (myosin, heavy polypeptide 9, non-muscle) forward
50 AGGAGACAAAGGCGCTATCA 30, reverse 50 GACTTCTCCAGCTC
GTGGAC 30, Glyceraldehyde 3-phosphate dehydrogenase-2 forward
50 TGTGTCCGTCGTGGATCTGA 30, reverse 50 CCTGCTTCACCACC
TTCTTGAT 30.
Data were captured on a 7900 HT fast real time PCR System
(Applied Biosystems) and analysed as a function of glyceraldehyde
3-phosphate dehydrogenase expression.
Aggregation and toxicity of
polyglutamine constructs
SK-N-SH and HeLa cells were grown in Dulbecco’s modiﬁed
eagle medium supplemented with 5% fetal calf serum, penicillin/
streptomycin and 2mM L-glutamine at 37 Ci n5 %C O 2.
Transfections were performed in 6 well plates using Lipofectamine or
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. Plasmids were enhanced green ﬂuorescent protein
(pEGFP-C1, Clontech) fused at its C terminus with an Huntington’s
disease gene exon 1 fragment with 74 polyQ repeats (EGFP-httQ74)
(Narain et al., 1999), wild-type Usp15 and mutant Usp15
(Usp15C783A) were a kind gift of Bettina Hetfeld (Hetfeld et al.,
2005). SK-N-SH cells were co-transfected with 1.5mg of Usp15 con-
struct or empty vector and 0.5mg EGFP-httQ74 and incubated for
24h. Small interfering RNA transfections in HeLa cells were carried
out using 50nM control (non-targeting SMARTpool), or speciﬁc ON-
TARGETplus SMARTpool (Dharmacon). After 24h cells were further
transfected with 0.5mg EGFP-httQ74 and incubated for 48h. Cells
were ﬁxed for 20min in 4% formaldehyde at room temperature.
Slides were mounted in Citiﬂuor (Citiﬂuor Ltd.) containing 40,6-diami-
dino-2-phenylindole (3mg/ml). Transfected cells were scored for
aggregation and cell death using an Eclipse E600 ﬂuorescence micro-
scope (plan-apo 60 /1.4 oil immersion lens) (Nikon). Cell death was
measured as the number of nuclei demonstrating apoptotic morphol-
ogy (fragmentation or pyknosis). At least 200 transfected cells per slide
were scored in triplicate with the scorer blinded to treatment and each
experiment was carried out on three independent occasions.
Results
Temsirolimus enhances rotarod
performance in a mouse model
of spinocerebellar ataxia type 3
Transgenic mice overexpressing full-length human ataxin-3
with an expanded polyglutamine repeat of 70 glutamines have
previously been shown to possess a neuropathological phenotype
(Bichelmeier et al., 2007). In our laboratory, the mice did not
demonstrate as severe a phenotype as previously reported.
Transgene expression was not seen to decrease lifespan and no
overt cellular phenotype was noted by staining of cerebellum with
calbindin or phosphorylated neuroﬁlament antibodies (data not
shown), although clear mutant ataxin-3 aggregation was observed
(see below). We examined the motor coordination of these mice
using rotarod performance. A decreased ability to walk on the
rotarod was observed in mice expressing expanded polyglutamine
ataxin-3 relative to non-transgenic littermate controls (Fig. 1A).
This decrease was most pronounced in young mice as the rotarod
performance of wild-type mice declined with age. Rotarod assess-
ment was the only motor phenotype that gave quantiﬁable read-
outs in the ﬁrst 6 months of life; we saw no clear effects with
tremor, fore- and hind-limb grip strength, wire manoeuvre or hind
limb grasping (data not shown).
We treated spinocerebellar ataxia type 3 transgenic mice with
temsirolimus, a water-soluble rapamycin analogue, or vehicle con-
trol administered by intraperitoneal injection exactly as described
previously (Ravikumar et al., 2004). Temsirolimus had no effect on
rotarod performance in wild-type mice (data not shown). The
polyQ repeat length of all animals in the trial was conﬁrmed as
being 70 (data not shown). Mice were tested for rotarod perfor-
mance at 5 weeks of age, before beginning temsirolimus treat-
ment. Animals were split into placebo and treatment groups
(within littermate groups) ensuring both groups had similar initial
rotarod performance (placebo 157 14s, treatment 150 16s;
not signiﬁcant by t-test). Treatment was started at 6 weeks of
age by which time transgenic mice already show decreased
rotarod performance (Fig. 1A). Performance was monitored
every second week until the mice reached 21 weeks of age.
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for longer on the accelerating rotarod test than placebo treated
mice (Fig. 1B).
Ataxin-3 transgenic mice did not show premature lethality in our
animal house, at least until 18 months. We lost two mice in the
study as a result of injection complications, one mouse was culled
due to peritonitis and another died acutely during injection (presum-
ably due to injection into a vessel or organ). In addition, two mice
died unexpectedly of unknown causes during the period of the trial.
Rapamycin up-regulates autophagy
in cortical neurons
Rapamycins, including temsirolimus, up-regulate autophagy by
inhibiting the kinase mTOR. We therefore conﬁrmed that
the mTOR pathway was inhibited in the brains of treated mice.
As we previously observed in a mouse model of Huntington’s
disease (Ravikumar et al., 2004), mice treated with temsirolimus
showed a decrease in immunoreactivity for phosphorylated S6
ribosomal protein, a downstream target of the mTOR pathway,
whilst immunoreactivity for total S6 ribosomal protein did not
change (Fig. 2A).
Inhibition of this pathway in vivo strongly suggests the
up-regulation of autophagy. A more direct assessment of auto-
phagy levels can be achieved by measuring LC3-II levels, as this
protein is speciﬁcally associated with autophagosomes. However,
demonstration of increased LC3-II levels in vivo is not possible as
neurons appear to clear autophagosomes very efﬁciently (Boland
et al., 2008). We therefore used primary neuronal culture to show
that treatment with rapamycin increases LC3-II levels (Fig. 2B and
C). This also allowed us to demonstrate that this increase in LC3-II
levels results from an increase in synthesis rather than a decrease
in degradation of autophagosomes, as increased levels were also
seen in the presence of baﬁlomycin-A1, an autophagy inhibitor
that blocks autophagosome lysosome fusion and therefore
LC3-II degradation (Fig. 2B and C). As demonstrated in vivo,
we observed that treatment of cortical neurons with rapamycin
inhibited the mTOR pathway. By western blotting we could
observe a decrease in phosphorylation of p70S6 kinase and eukar-
yotic initiation factor 4E-binding-protein-1, both substrates for
mTOR, as well as decreased levels of phosphorylated S6 protein,
a substrate of p70S6 kinase (Fig. 2D and E).
Temsirolimus treatment decreases
aggregate number in the brains of
ataxin-3 transgenic mice
To assess the cellular effects associated with the improvement in
behavioural testing seen in temsirolimus treated mice we looked at
ataxin-3 positive aggregates in the brains of treated and control
mice. Mice treated with placebo show a large number of aggre-
gates throughout the brain. We scored aggregates in the motor
cortex as this region demonstrated a high level of aggregates,
while aggregate number could still be counted accurately,
making it the most suitable region for this assay. Mice were trea-
ted for two months with temsirolimus or placebo beginning at
5 weeks of age (as for rotarod performance). Mice were then
sacriﬁced and the number of aggregates in the motor cortex
quantiﬁed. Aggregate number was signiﬁcantly reduced in mice
treated with temsirolimus compared to placebo treated mice
(Fig. 3A and B).
Temsirolimus reduces cytoplasmic
levels of expanded ataxin-3
In spinocerebellar ataxia type 3, ataxin-3 aggregates show predo-
minantly nuclear localization, and this nuclear localization is
required for toxicity (Bichelmeier et al., 2007). Autophagy is a
cytoplasmic process and we were therefore interested to increase
our understanding of the cellular localization of the effect of
temsirolimus. We measured soluble protein levels in the
Figure 1 Temsirolimus administration improves rotarod
performance in ataxin-3 transgenic mice. (A) Mice expressing
mutant ataxin-3 (black line) demonstrate a decreased latency
to fall on the accelerating rotarod test compared with
non-transgenic littermate controls (grey line). Data shown
represent mean values and standard error. P50.001 by
ANOVA. (B) Mice administered temsirolimus (CCI-779; black
line) show an increase in performance on the rotarod over
placebo treated control animals (grey line) throughout the
period of the study. P50.001 by ANOVA. For placebo treated
mice n=17 at each time point. For temsirolimus treated mice
n=17 up to and including 14 weeks, n=15 at 16 weeks and
n=14 thereafter.
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soluble 70Q ataxin-3 were reduced in the cytoplasm of treated
mouse brains, but not in the nuclear fraction (Fig. 3C–E). We also
observed that, while the levels of the expanded polyglutamine
ataxin-3 protein are reduced in the cytoplasmic fraction, there
was no change in the levels of the endogenous wild-type
ataxin-3 protein in either the cytoplasm or the nucleus. This sug-
gests the mutant, aggregate-prone protein is more efﬁciently
degraded by autophagy than the wild-type, endogenous protein.
This is entirely consistent with our previous data from cell culture
models of different aggregate-prone proteins, where the mutant
form is much more dependent on autophagy for clearance
(Williams et al., 2008).
Modest effects on transcription are
seen with the protective effect of
temsirolimus
Whilst the pathogenisis of spinocerebellar ataxia type 3 is
unknown it has been hypothesized that transcriptional dysregula-
tion may play a role (reviewed in Riley and Orr, 2006). In order to
investigate the importance of transcriptional changes in disease
pathogenesis we used a microarray approach to look at changes
in gene expression in ataxin-3 transgenic mice and the reversal of
these changes associated with the improved phenotype in temsir-
olimus treated mice. As our ataxin-3 transgenic mice do not have
Figure 2 Temsirolimus inhibits the mTOR pathway in vivo, as rapamycin does in cultured primary neurons. (A) Sections from mouse
brains treated with either temsirolimus (CCI-779) or placebo were immunostained for phosphorylated S6 protein (Phospho-S6,
top panels) or total S6 protein (bottom panels), nuclei were counterstained with 40,6-diamidino-2-phenylindole (DAPI; blue).
Total S6 immunoreactivity was seen in the perinuclear region of all cells. In placebo treated animals some cells stained positive for
phosphorylated S6, however, this staining was not seen in sections from animals treated with temsirolimus. Scale bar represents 5mm
and is valid for all panels. In cultured primary neurons, LC3-II levels were assessed by western blot (B). Two different exposures are
shown to allow comparison of weaker bands in untreated lanes ( Baf A1) and stronger bands in Baﬁlomycin A1 (+Baf A1) lanes
without saturation. Densitometric quantiﬁcation of LC3-II levels relative to actin in triplicate experiments is shown in (C).
  P50.01 and
 P50.05 by t-test. Effect of rapamycin treatment of phosphorylation of downstream mTOR targets was investigated by western
blotting, (D) phosphorylated p70 S6 kinase levels and phosphorylated S6 ribosomal protein and (E) phosphorylated eukaryotic initiation
factor 4E-binding-protein (EBP)-1.
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be associated with early disease. We hypothesized that investigat-
ing gene expression changes that are associated with the improve-
ment in the phenotype seen in temsirolimus treated ataxin-3
transgenic mice would allow us to identify gene expression
changes that are important in the progression of the disease,
since temsirolimus administration reduces the levels of the primary
‘toxin’, mutant ataxin-3.
RNA was extracted from the brains of four groups of mice,
wild-type or ataxin-3 transgenic mice administered either placebo
or temsirolimus. From these datasets we identiﬁed transcripts
that were altered by more than 1.5-fold in transgenic, control
(placebo-treated) animals compared to wild-type, control animals.
This analysis identiﬁed 91 transcripts. The overall magnitude of
the changes in transcription were small with 77 genes showing
changes of between 1.5- and 2-fold, 13 genes showing changes
between 2- and 3-fold and one gene, CUG triplet repeat, RNA
binding protein 2 showing a 3.16-fold down-regulation in trans-
genic versus non-transgenic placebo treated animals. This is of
interest as another CUG repeat binding protein, muscleblind
(Miller et al., 2000), has been shown to be a modulator of
ataxin-3 toxicity in Drosophila (Li et al., 2008). Overexpression
Figure 3 Aggregation and clearance of ataxin-3 with temsirolimus treatment. (A) Ataxin-3 staining in the motor cortex reveals
the presence of aggregates in transgenic mice. Control (placebo) mice show more aggregates in the motor cortex than treated
(temsirolimus, CCI-779) animals. Examples of aggregates are indicated by arrows in both treated and untreated brains. Scale bar
represents 20mm and is valid for all pictures. Quantiﬁcation of the mean number of aggregates is shown in (B). Aggregates were
counted in the motor cortex on three sections each for ﬁve mice in each treatment group (n=5).
 P50.05 placebo versus temsirolimus
treated mice by t-test. Levels of endogenous, and transgenic mutant ataxin-3 in placebo (cont) and drug treated (CCI) mice were
measured by western blotting (C). The expanded polyglutamine stretch of the mutant protein results in its slower migration in the gel
(upper band). Tubulin is used as a control to ensure equal loading of cytoplasmic samples and Histone H3 for nuclear samples. The
black line marks where lanes of the western have been omitted for the sake of clarity. Quantiﬁcation by densitometry of ataxin-3 levels
in nuclear protein extracts (D) and cytosolic extracts (E) from three mice corrected for the level of tubulin (n=3).
  P50.01 placebo
versus temsirolimus treated mice by t-test.
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by a mechanism involving toxicity of the mutant RNA
(Li et al., 2008).
From the 91 transcripts altered in wild-type versus transgenic
animals we selected those that were also changed in the opposite
direction (i.e. returned to normal levels) in transgenic animals
treated with temsirolimus (Fig. 4A). This analysis identiﬁed only
16 genes (Table 1) whose expression was decreased in transgenic
ataxin-3 mice and increased in transgenic mice treated with tem-
sirolimus. We did not identify any genes whose expression
increased in transgenic ataxin-3 mice and decreased in temsiroli-
mus treated mice.
Expression changes seen by microarray were veriﬁed by quan-
titative PCR. Of the ﬁrst three genes we looked at, we conﬁrmed
a decrease in expression of Usp15 and Grik2 between wild-type
and ataxin-3 transgenic mice, which were reversed in mice treated
with temsirolimus (Fig. 4B). However, no decrease was seen in
Tloc1 levels in ataxin-3 transgenic mice compared to wild-type
mice, although an increase in Tloc1 levels was seen following
temsirolimus administration. Of the remaining 10 known genes
Figure 4 Microarray analysis of transgenic ataxin-3 mice. Microarray analysis of four experimental groups of mice was carried out and
changes between pairs of experimental groups were identiﬁed. (A) Shows a representation of these comparisons as a Venn diagram.
The number of genes with altered regulation are given for each pair of groups. The shaded region identiﬁes the transcripts selected i.e.
those altered in wild-type versus transgenic mice that were normalized following the treatment of mice with temsirolimus (see Table 1).
Microarray changes were veriﬁed by quantitative PCR. (B) Shows mRNA relative expression levels of Tloc1, Usp15 and Grik2,
expression levels are normalized to wild-type, placebo treated mice (black bars). Grey bars represent placebo treated, ataxin-3
transgenic mice and white bars temsirolimus treated ataxin-3 transgenic mice.
 P50.05 and
   P50.001 by t-test. (C) Additional
veriﬁcation of transcript alterations in wild-type versus ataxin-3 transgenic mice. mRNA was extracted from brains of untreated mice
and expression levels of measured relative to the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase 2. Expression was
normalized to levels in wild-type mice and the relative levels in ataxin-3 transgenic mice are shown.
 P50.05 and
  P50.01 by t-test,
n=3, other comparisons are not statistically signiﬁcant. Protein levels of Usp15 were analysed in 3.5–4 month old wild-type (n=4) and
transgenic ataxin-3 (n=6) mouse brain by western blotting (D). Protein levels were quantiﬁed by densitometry relative to the level of
the loading control, actin (E).
  P50.01 by t-test. (F) mRNA expression of Usp15 was measured in brains of 6 month old wild-type
and huntingtin (Htt) transgenic mice. Expression levels are corrected for the housekeeping gene SDHA and are shown relative to wild-
type mice.
 P50.05 by t-test. (G) Protein levels of Usp15 were investigated by western blot with actin as a loading control.
Protein levels were quantiﬁed by densitometry relative to the level of actin (H).
   P50.001 by t-test.
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fully amplify mRNA transcripts from seven (Bcl2l11, Dgki and
Mnab PCRs were unsuccessful) and we conﬁrmed decreases in
Alkbh5 and Alcam mRNA levels in ataxin-3 transgenic mice com-
pared to wild-type (Fig. 4C). Whilst mRNA levels were clearly
altered for both Usp15 and Grik2 changes at the protein level
could only be observed with Usp15 (Fig. 4D and E). This may
be because western blotting is a less sensitive method of detecting
changes and small changes in Grik2 level may be missed, or
because the rate of transcription of Grik2 is not an important
step in the control of protein expression level. Additionally, in
agreement with the quantitative PCR results we did not observe
any changes in the level of protein expression of Sfpq and RORa
(Supplementary Fig. 1).
Decreases in ubiquitin speciﬁc
peptidase-15 levels are seen in mice
expressing mutant ataxin-3 and mutant
huntingtin
The identiﬁcation and veriﬁcation of changes in Usp15, a deubi-
quitinating protein, was of great interest. Ataxin-3 has been
previously shown to possess deubiquitinating activity (Burnett
et al., 2003) the N-terminal Josephin domain bears homology to
the UBP (ubiquitin speciﬁc protease) family of deubiquitinating
enzymes, which includes Usp15 (Scheel et al., 2003).
Additionally, the deubiquitinating activity of ataxin-3 has been
shown to be regulated by ubiquitination of ataxin-3 itself (Todi
et al., 2009). We were therefore interested to investigate further
the potential role of changes in expression level of Usp15 in spi-
nocerebellar ataxia type 3.
To establish if this decrease was speciﬁc for spinocerebellar
ataxia type 3 and associated with the function of ataxin-3, we
investigated the levels of both Usp15 mRNA and protein in a
mouse model of another polyglutamine disorder, Huntington’s
disease (Schilling et al., 1999). These mice express an N-terminal
fragment of huntingtin (171 amino acids) with an expanded poly-
glutamine repeat region of 82 glutamines. As for mutant ataxin-3
transgenic mice, mutant huntingtin transgenic mice also showed a
decrease in mRNA and protein levels of Usp15 (Fig. 4F–H).
Overexpression of ubiquitin speciﬁc
peptidase-15 results in an increase in
polyglutamine aggregation
To investigate further the relationship between Usp15 and poly-
glutamine containing proteins we looked at the effect of altering
levels of Usp15 expression in cells. As mutant ataxin-3 has minimal
toxicity and does not form aggregates in cell culture systems,
exon 1 of huntingtin with an expanded polyglutamine repeat
region of 74 glutamines was used in toxicity and aggregation
studies. To mimic the alteration in Usp15 levels seen in mutant
ataxin-3 and huntingtin transgenic mice, cells were treated with
small interfering RNA against Usp15. This resulted in a decrease in
Usp15 protein levels (Supplementary Fig. 2A) although no changes
in aggregation or toxicity of mutant huntingtin were observed
(Supplementary Fig. 2B and C). Whilst decreasing Usp15 levels
showed no effect, overexpression of Usp15 resulted in an increase
in aggregation levels (Supplementary Fig. 2D). Usp15 is able to
cleave both polyubiquitin chains and monoubiquitinated substrates
(Hetfeld et al., 2005). The effect of Usp15 overexpression on
polyglutamine aggregation is independent of its polyubiquitin
Table 1 Genes identiﬁed to be down-regulated in ataxin-3 transgenic mice versus non-transgenic mice and normalized by
temsirolimus treatment










1417472_at Myosin, heavy polypeptide 9, non-muscle Myh9 0.036 1.50 0.006 2.71
1436326_at RAR-related orphan receptor alpha RORa 0.019 1.53 0.016 1.54
1436891_at Ubiquitin speciﬁc peptidase 15 Usp15 0.009 1.50 0.006 1.91
1436898_at Splicing factor proline/glutamine rich Sfpq 0.002 1.86 0.001 1.85
1437728_at AlkB, alkylation repair homolog 5 (E. coli) Alkbh5 0.004 1.62 0.001 1.93
1438268_at Membrane associated DNA binding protein Mnab 0.003 2.19 0.026 1.53
1438403_s_at Metastasis associated lung adenocarcinoma transcript 1 malat1 4.49E-04 1.70 0.001 1.72
1439940_at RIKEN cDNA 2900019G14 0.001 1.87 0.002 1.77
1439946_at Myocyte enhancer factor 2C Mef2c 0.003 2.23 0.015 1.61
1440602_at Glutamate receptor, ionotropic, kainate 2 (beta 2) Grik2 0.003 1.62 0.004 1.69
1442813_at Diacylglycerol kinase, iota Dgki 0.032 1.64 0.007 1.83
1443086_at Activated leukocyte cell adhesion molecule Alcam 0.014 1.54 0.002 1.60
1444811_at Translocation protein 1 Tloc1 0.036 1.62 0.045 1.51
1445676_at RIKEN clone C230043A04 0.007 1.59 0.004 1.55
1456005_a_at BCL2-like 11 (apoptosis facilitator) Bcl2l11 0.038 1.65 0.024 1.68
1457817_at Breast carcinoma ampliﬁed sequence 3 Bcas3 0.004 1.52 6.51E-04 1.60
SCA3=Spinocerebellar ataxia type 3.
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protein, Usp15C783A, which is unable to degrade polyubiquitin
substrates (Hetfeld et al., 2005), showed the same effect as the
wild-type protein. This mutant Usp15 is still able to cleave mono-
ubiquitinated substrates. Despite increasing aggregation, over-
expression of Usp15 did not increase toxicity of the expanded
polyglutamine protein (Supplementary Fig. 2E).
Discussion
We have shown that administration of an mTOR inhibitor, temsir-
olimus, ameliorates the effects of ataxin-3 overexpression in a
mouse model of spinocerebellar ataxia type 3. mTOR inhibition
induces autophagy in all cells tested, from S. cerevisiae to mam-
malian neurons (Noda and Ohsumi, 1998; Boland et al., 2008).
While rapamycin induces autophagy in primary neurons, this will
be difﬁcult to demonstrate deﬁnitively in vivo as neurons appear
to clear autophagosomes very efﬁciently (Boland et al., 2008).
However, consistent with mTOR inhibition inducing autophagy,
ataxin-3 transgenic mice treated with temsirolimus showed
decreased levels of phosphorylated S6 ribosomal protein (a down-
stream target of the mTOR pathway), and levels the mutant
protein in the cytosol were decreased, as were the number of
aggregates.
Temsirolimus treatment also resulted in an improvement in
motor coordination as measured by rotarod performance. As the
phenotype of the ataxin-3 overexpressing mice used in this study
is mild, we were unable to assess a broader range of phenotypes.
Ideally, it would be helpful to test this therapeutic strategy in other
rodent models of spinocerebellar ataxia type 3 in future, if they
show stronger and more robust phenotypes. Despite this, our
study demonstrates that temsirolimus may have additional thera-
peutic values beyond the effect previously demonstrated by
pre-symptomatic treatment in a mouse model of Huntington’s
disease (Ravikumar et al., 2004). Indeed, autophagy induction
may be effective even if initiated after disease onset. However,
treatment strategies aiming to enhance protein clearance may be
most effective prior to overt disease onset or early in disease
course. In an elegant study, Orr and colleagues developed an
inducible mouse model of the polyglutamine disease spinocerebel-
lar ataxia type 1 (Zu et al., 2004). They demonstrated that, if
transgene expression was turned off early in the disease course,
there was excellent recovery, but switching off the mutant trans-
gene later in the disease did not result in the same extent of
recovery. However, as human diseases do not progress as rapidly
as most of the mouse models used for preclinical compound
testing, there may be an increased window of opportunity for
treatment of patients.
In our study we observe a reduced level of soluble 70Q ataxin-3
in the cytoplasm of treated mouse brains, but not in the nuclear
fraction (Fig. 3C–E). We believe that autophagy predominantly
clears the soluble species of the mutant protein, rather than the
large aggregates that are visible by light microscopy (discussed in
Rubinsztein, 2006). However, the number of cells with aggregates
is directly proportional to expression of the mutant protein
(Narain et al., 1999). The aggregate load in the nucleus is likely
to change when cytosolic ataxin-3 is depleted, since the protein
shuttles between the nucleus and cytoplasm (Pozzi et al., 2008).
It is possible that changes in the nuclear soluble pool assessed by
western blotting are more difﬁcult to quantify than changes in
aggregate number.
While the major contributing factor to the loss of toxicity
of ataxin-3 by temsirolimus is likely to be the up-regulation
of autophagy, there are also other factors that could play a pro-
tective role. Firstly, as well as increasing protein clearance, up-
regulation of autophagy has been demonstrated to have cytopro-
tective effects against apoptotic death via the intrinsic,
mitochondria-dependant pathway (Ravikumar et al., 2006).
Secondly, in addition to inducing autophagy, rapamycin has
been suggested to act to reduce toxicity of aggregate-prone pro-
teins by decreasing protein translation (King et al., 2008).
However, it is important to point out that the clearance of these
aggregate-prone proteins is impaired when one blocks autophagy
via a wide range of mTOR-independent chemical and genetic
pathways (Ravikumar et al., 2002; Berger et al., 2006). Like-
wise, induction of autophagy via mTOR-independent pathways
enhances the clearance of aggregate-prone proteins and is protec-
tive in different polyglutamine models in cells, ﬂies and zebraﬁsh
(Williams et al., 2008). Finally, the beneﬁcial effects of rapamycin
in ﬂy models of these diseases appear to be autophagy-
dependent, as rapamycin had no effects on toxicity in ﬂies expres-
sing different aggregate-prone mutant proteins on a background
of reduced activity of different autophagy genes (Berger et al.,
2006; Pandey et al., 2007). While these data suggest that rapa-
mycin treatment is dependent on autophagy in Drosophila,w e
cannot exclude an additional effect of temsirolimus via mild trans-
lational inhibition in the spinocerebellar ataxia type 3 transgenic
mice. However, any such effect could not be a consequence of
global translational inhibition, as we observed no changes in the
levels of wild-type ataxin-3, consistent with previous data suggest-
ing that the mutant forms of these proteins are much more
dependent on autophagy for their clearance compared to their
wild-type forms (discussed in Rubinsztein, 2006).
Treatment of proteinopathies with drugs that up-regulate
autophagy has shown tantalizing results in a small trial of another
human disease associated with intracytosolic inclusion formation,
amyotrophic lateral sclerosis. Lithium induces autophagy by low-
ering intracellular inositol or inositol 1,4,5-trisphosphate levels in
an mTOR independent manner (Sarkar et al., 2005) and delays
disease progression in patients with amyotrophic lateral sclerosis
and in a mouse model of amyotrophic lateral sclerosis over-
expressing a mutant form of Superoxide dismutase 1 (Fornai
et al., 2008). While lithium did induce autophagy in neurons in
the mouse models and facilitated Superoxide dismutase 1 clear-
ance, it is possible that this drug had additional autophagy-
independent protective effects. Nevertheless, the mTOR-
independent nature of the action of lithium and its cytoprotective
and autophagy- inducing properties offer the possibility for the
development of treatment rationales involving simultaneous
lithium and rapamycin administration (Sarkar et al., 2008).
Therefore there may be much potential for the use of drugs upre-
gulating autophagy in the treatment of a diverse range of
proteinopathies.
102 | Brain 2010: 133; 93–104 F. M. Menzies et al.The mouse model described here and the rescue seen with the
administration of temsirolimus offered the possibility to investigate
the role of transcriptional dysregulation in spinocerebellar ataxia
type 3. Polyglutamine disorders have been suggested to result
from an altered transcription, (reviewed in Riley and Orr, 2006).
The evidence for this comes largely from studies of Huntington’s
disease, but has also been suggested in spinocerebellar ataxia
type 3 due to the observations that ataxin-3 may affect histone
acetylation (Li et al., 2002; Evert et al., 2006). In this study we
attempted to identify changes in transcription that may be impor-
tant in the early disease progression of spinocerebellar ataxia
type 3. Ataxin-3 transgenic mice show a relatively mild phenotype,
this is advantageous as secondary transcriptional changes that are
not causative of disease phenotype are likely to be reduced. Add-
itionally, focusing on transcripts that were reverted to normal
expression levels with a reversal of the disease phenotype by
temsirolimus allowed us to look more directly for transcriptional
changes speciﬁc to disease pathogenesis. Surprisingly we observed
only a few such changes in gene expression. It is also of note that
the magnitude of expression changes seen was small, with most
transcripts showing changes of 1.5–2-fold.
We were able to conﬁrm the changes in expression level of
Usp15 seen by microarray at both the mRNA and protein level.
Furthermore, its expression was also decreased in mutant hunting-
tin transgenic mice. However, changes in expression of Usp15 did
not modulate toxicity of a model polyglutamine protein in cell
culture. Whilst this appears to suggest that changes in Usp15
expression are not a major contributing factor to the pathogenesis
of spinocerebellar ataxia type 3, it is also possible that changes in
this gene may be important in the slowly progressing phenotype
seen in mouse models and in the human disease, but not in the
acute cell system used here.
In conclusion, we have demonstrated that treatment of trans-
genic ataxin-3 mice with temsirolimus, a drug which up-regulates
autophagy, leads to a decrease in protein levels of the mutant
polyglutamine protein and that this is associated with improved
behavioural outcomes in the mice. Transgenic ataxin-3 mice also
demonstrate a mild perturbation in transcription which is partially
relieved by treatment with temsirolimus. However, the importance
of these transcriptional alterations in the pathogenesis of spinocer-
ebellar ataxia type 3 remains unclear.
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